Skip to content
Menu

Edgewise Therapeutics, Inc. EWTX

Full chart Compare
Set alert

Price alert · EWTX

All alert types
39.91 USD -1.27 (-3.07%)

Regular-session close

39.91 0.00 0.00%

After hours · Nov 20, 4:01 PM ET

39.71 Day range 41.40
19.76 52-week range 48.78
YTD
+60.78%
1 year
+79.35%

5D -4.33 (-9.34%)

42444648WedThuFriMonTue42.04
Market cap
4.37B
EPS (ttm)
8.38
Shares out
109.48M
P/E ratio
4.76
Forward P/E
-20.34
YTD return
+60.78%
1-year return
+79.35%
50-day average
41.23
200-day average
37.27
Enterprise value
2.77B
Volume
1.11M
Avg volume
1.53M
Open
40.81
Previous close
41.17
Day's range
39.71 – 41.40
52-week range
19.76 – 48.78
Beta
0.40
Analysts
Strong Buy
Price target
55.42 (+38.9%)
Earnings date
Feb 25, 2027

Key statistics

Price / book
2.67
Free cash flow
6.55M
Total cash
1.74B
Total debt
3.38M
Return on equity
92.14%
Short % of float
16.29%

Fundamental scorecard

9 of 25 checks passed on EWTX’s reported financials

ValueGrowthProfitabilityHealthDividend

9of 25 checks passed

  • Value 2 of 5
  • Growth 1 of 5
  • Profitability 2 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
EWTX Revenue — quarterly 0
EWTX Net income — quarterly 1.17B
EWTX EPS — quarterly 10.71

Earnings

EWTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-0.42252———
Nov 4, 2026Sep 30, 2026-0.531989.65+10.18+1,913.98%
Aug 6, 2026Jun 30, 2026-0.46769-0.53-0.06-13.32%
May 7, 2026Mar 31, 2026-0.50-0.46+0.04+8.00%
Feb 26, 2026Dec 31, 2025-0.43-0.47-0.04-9.30%
Nov 6, 2025Sep 30, 2025-0.40-0.39+0.01+2.50%

Upgrades / downgrades

EWTX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026WedbushmainOutperformOutperform
Oct 16, 2026William Blairinit—Outperform
Sep 21, 2026HC Wainwright & Co.mainBuyBuy
Aug 20, 2026JP MorganmainOverweightOverweight
Aug 11, 2026Goldman SachsmainNeutralNeutral
Jul 20, 2026Evercore ISI GroupmainOutperformOutperform

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on EWTX — it syncs with the Stock Master app.

Insider holders

EWTX insider holders
InsiderRelationLatest transactionDateShares held
CARRUTHERS ROBERT MICHAELChief Financial OfficerConversion of Exercise of derivative securityAug 11, 202586,162
DERAKHSHAN BEHRADOfficerConversion of Exercise of derivative securityAug 11, 202631,826
DONOVAN JOANNE MOfficerSaleNov 15, 20268,139
EDRIS BADREDDINDirectorConversion of Exercise of derivative securityJan 20, 202619,820
FOX JONATHAN CDirectorStock Award(Grant)Jun 30, 202624,833
KOCH KEVINChief Executive OfficerConversion of Exercise of derivative securityAug 11, 202652,488

Institution ownership

EWTX institution ownership
Holder% heldSharesValueReported
Orbimed Advisors LLC.14.17%15,518,492618.88MSep 29, 2026
Paradigm Biocapital Advisors LP9.85%10,778,665429.85MSep 29, 2026
RA Capital Management, L.P.7.67%8,392,730334.70MSep 29, 2026
Janus Henderson Group Ltd.6.67%7,298,520291.06MSep 29, 2026
Blackrock Inc.6.64%7,274,226290.10MSep 29, 2026
Novo Holdings A/S4.89%5,350,000213.36MSep 29, 2026

Fund ownership

EWTX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.65%2,902,230115.74MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.69%1,855,09173.98MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.79%864,63834.48MJun 29, 2026
American Century Mutual Funds, Inc.-Small Cap Growth Fund0.78%856,21434.15MSep 29, 2026
Victory Portfolios IV-Victory Pioneer Select Mid Cap Growth Fund0.73%794,39331.68MAug 30, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.72%783,18931.23MAug 30, 2026